Gilteritinib in FLT3 mutated AML patients

Gilteritinib in FLT3 mutated AML patients

obr

1 year
161 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting 2018.
Up Next Autoplay